| Year |
Citation |
Score |
| 2019 |
Vanderwerff BR, Church KJ, Kawas LH, Harding JW. Comparative characterization of the HGF/Met and MSP/Ron systems in primary pancreatic adenocarcinoma. Cytokine. 123: 154762. PMID 31254927 DOI: 10.1016/J.Cyto.2019.154762 |
0.622 |
|
| 2015 |
Uribe PM, Kawas LH, Harding JW, Coffin AB. Hepatocyte growth factor mimetic protects lateral line hair cells from aminoglycoside exposure. Frontiers in Cellular Neuroscience. 9: 3. PMID 25674052 DOI: 10.3389/Fncel.2015.00003 |
0.608 |
|
| 2015 |
Wright JW, Kawas LH, Harding JW. The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases. Progress in Neurobiology. 125: 26-46. PMID 25455861 DOI: 10.1016/J.Pneurobio.2014.11.004 |
0.547 |
|
| 2015 |
Vanderwerff B, Church K, Kawas L, Harding J. Abstract 3922: Novel hepatocyte growth factor and macrophage stimulating protein antagonists for the treatment of castration-resistant prostate cancer Cancer Research. 75: 3922-3922. DOI: 10.1158/1538-7445.Am2015-3922 |
0.552 |
|
| 2014 |
Benoist CC, Kawas LH, Zhu M, Tyson KA, Stillmaker L, Appleyard SM, Wright JW, Wayman GA, Harding JW. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system. The Journal of Pharmacology and Experimental Therapeutics. 351: 390-402. PMID 25187433 DOI: 10.1124/Jpet.114.218735 |
0.733 |
|
| 2014 |
Kawas LH, Church KJ, Lange M, Mcmicheal M, Yamamoto B, Harding JW. Abstract 729: Norleual a hepatocyte growth factor/c-Met inhibitor blocks malignant phenotypes in cancerous cells Cancer Research. 74: 729-729. DOI: 10.1158/1538-7445.Am2014-729 |
0.739 |
|
| 2014 |
Church KJ, Kawas L, Harding J, Lang M, McMicheal M. Abstract 2708: Development of allosteric regulators of the dimerization domains of the plasminogen-related growth factor family for the treatment of pancreatic cancer Cancer Research. 74: 2708-2708. DOI: 10.1158/1538-7445.Am2014-2708 |
0.709 |
|
| 2013 |
Wright JW, Kawas LH, Harding JW. A Role for the Brain RAS in Alzheimer's and Parkinson's Diseases. Frontiers in Endocrinology. 4: 158. PMID 24298267 DOI: 10.3389/Fendo.2013.00158 |
0.553 |
|
| 2013 |
McCoy AT, Benoist CC, Wright JW, Kawas LH, Bule-Ghogare JM, Zhu M, Appleyard SM, Wayman GA, Harding JW. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. The Journal of Pharmacology and Experimental Therapeutics. 344: 141-54. PMID 23055539 DOI: 10.1124/Jpet.112.199497 |
0.726 |
|
| 2013 |
Kawas LH, Benoist CC, Harding JW, Wayman GA, Abu-Lail NI. Nanoscale mapping of the Met receptor on hippocampal neurons by AFM and confocal microscopy. Nanomedicine : Nanotechnology, Biology, and Medicine. 9: 428-38. PMID 22960190 DOI: 10.1016/J.Nano.2012.08.008 |
0.644 |
|
| 2013 |
Kawas LH, Harris P, Church K, Wright JW, Harding JW. Abstract 926: The angiotensin IV analog Norleual acts as a hepatocyte growth factor/c-Met inhibitor in pancreatic cancer cells. Cancer Research. 73: 926-926. DOI: 10.1158/1538-7445.Am2013-926 |
0.681 |
|
| 2012 |
Wright JW, Wilson WL, Wakeling V, Boydstun AS, Jensen A, Kawas L, Harding JW. The Hepatocyte Growth Factor/c-Met Antagonist, Divalinal-Angiotensin IV, Blocks the Acquisition of Methamphetamine Dependent Conditioned Place Preference in Rats. Brain Sciences. 2: 298-318. PMID 24961196 DOI: 10.3390/Brainsci2030298 |
0.585 |
|
| 2012 |
Kawas LH, McCoy AT, Yamamoto BJ, Wright JW, Harding JW. Development of angiotensin IV analogs as hepatocyte growth factor/Met modifiers. The Journal of Pharmacology and Experimental Therapeutics. 340: 539-48. PMID 22129598 DOI: 10.1124/Jpet.111.188136 |
0.706 |
|
| 2012 |
Kawas LH, Ward BC, Mojica C, Wright JW, Harding JW. Abstract B3: Angiotensin IV-Related Hepatocyte Growth Factor Antagonists act as Anti-Angiogenic Anti-Cancer Agents Clinical Cancer Research. 18: B3-B3. DOI: 10.1158/1078-0432.Mechres-B3 |
0.628 |
|
| 2011 |
Kawas LH, Yamamoto BJ, Wright JW, Harding JW. Mimics of the dimerization domain of hepatocyte growth factor exhibit anti-Met and anticancer activity. The Journal of Pharmacology and Experimental Therapeutics. 339: 509-18. PMID 21859930 DOI: 10.1124/Jpet.111.185694 |
0.744 |
|
| 2011 |
Kawas LH, Harding JW, Yamamoto BJ, Wright JW. Abstract 1356: The Hinge (linker) region of the Hepatocyte Growth Factor (HGF) peptide sequence can act as Hepatocyte Growth Factor/c-Met inhibitor Cancer Research. 71: 1356-1356. DOI: 10.1158/1538-7445.Am2011-1356 |
0.743 |
|
| Show low-probability matches. |